Arbutus Biopharma
ABUS
ABUS
118 hedge funds and large institutions have $215M invested in Arbutus Biopharma in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 35 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4.77% less ownership
Funds ownership: 51.22% → 46.45% (-4.8%)
11% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 35
Holders
118
Holding in Top 10
4
Calls
$12.8M
Puts
$1.63M
Top Buyers
| 1 | +$7.74M | |
| 2 | +$5.34M | |
| 3 | +$4.93M | |
| 4 |
CCP
Corbin Capital Partners
New York
|
+$2.2M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.16M |
Top Sellers
| 1 | -$13.3M | |
| 2 | -$3.6M | |
| 3 | -$3.34M | |
| 4 |
TSC
Two Seas Capital
Rye,
New York
|
-$3.1M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.04M |